AGC Biologics has teamed up with Ono Pharmaceuticals as CDMO.

Guide: Together, the two companies will produce biopharmaceons in clinical development.
, Aug. 13, 2020 /AGENCY/-- CDMO AGC Biologics announced that it has teamed up with Ono Pharmaceutical Co., Ltd. to produce new and innovative biopharmaceers in clinical development.
ono is a research and development-oriented pharmaceutical company dedicated to the discovery and development of innovative drugs.
Womack, chief commercial officer of AMC Biologics, said: "We are delighted to be able to start this partnership with Ono.
hope to work closely with Ono to produce innovative and important therapeutic drugs.
" global network of AGC Biologics spans three continents, with facilities that comply with cGMP (Dynamic Drug Production Management Practices) in Seattle, Washington, Bolton, Colorado, Copenhagen, Denmark, Heidelberg, Italy, Milan and Bresso, Italy, and Chiba, Japan.
company's outstanding services include the development and manufacture of therapeutic proteins, proton DNA, viral vectors and genetically engineered cells based on mammals and microorganisms.
Ono, based in Osaka, is committed to creating innovative pharmaceuticals in specific areas.
focuses on oncology, immunology, neurology and specialist research with high medical needs and sees it as a priority area for the discovery and development of innovative medicines.
AMC Biologics introduction APC Biologics is a leading global contract development and production organization (CDMO) with a strong commitment to providing the highest standards of service to our customers and partners.
company currently employs more than 1,300 people worldwide.
the company has decades of experience in CDMO development and manufacturing, including in commercial market supply, and has been approved by the U.S. Food and Drug Administration (FDA), the Japan Pharmaceutical Medical Machines Agency (PDMA) and the European Medicines Agency (EMA).
AMC Biologics offers a wealth of industry expertise and unique customization services.
's integrated services include cell line development, biotechnology development, formulation, analytical testing, antibody drug development and binding, cell banking and storage, and protein expression, including the company's proprietary CHEF1®Expression System for mammals.
AGCBiologics is committed to continuous innovation, providing technical creativity to address our customers' most complex challenges, including a "fast track" program dedicated to orphan medicines and rare diseases.
.